Latest news with #AlligatorBioscience
Yahoo
03-06-2025
- Business
- Yahoo
Biomarker Data from Alligator Bioscience's OPTIMIZE-1 Trial Presented at ASCO 2025 Annual Meeting
LUND, SE / / June 3, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that biomarker data from its OPTIMIZE-1 clinical trial were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. OPTIMIZE-1 is a Phase 1b/2 trial evaluating mitazalimab in combination with mFOLFIRINOX in first-line metastatic pancreatic cancer (mPDAC). The study has demonstrated strong clinical outcomes to date, including a ~30% survival rate at 24 months and a median overall survival of 14.9 months. The biomarker analyses highlighted mitazalimab's immunological mechanism of action, with immune activation in responding patients and gene signatures associated with clinical benefit and improved survival. These results support continued development of mitazalimab, including a planned confirmatory trial in mPDAC. "ASCO continues to be a cornerstone event for clinical oncology, and it was a privilege to share our OPTIMIZE-1 data with the international community," said Søren Bregenholt, CEO of Alligator Bioscience. "The high level of engagement and many productive meetings we've had during the conference further validate the growing interest in mitazalimab and its potential in pancreatic cancer." The presentation poster is available on Alligator's website . Alligator's participation at ASCO is part of its broader commitment to scientific collaboration and strategic business development. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 8:45 a.m. CEST on 3 June 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit . Attachments Biomarker data from Alligator Bioscience's OPTIMIZE-1 trial presented at ASCO 2025 Annual Meeting SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
Alligator Bioscience AB Carries Out Directed Issues to Guarantors in Connection with Exercise of Warrants Series TO 12
LUND, SE / / May 26, 2025 / Alligator Bioscience (STO:ATORX) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The Board of Directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company") has today, based on the authorization granted by the annual general meeting on 7 May 2025, resolved on a directed issue of 2,730,708 ordinary shares (the "Directed Issue") to the guarantors who have entered into top guarantee commitments to secure the subscription of warrants series TO 12 ("TO 12") in the event that the exercise rate for TO 12 was below approximately 85 percent. As the exercise rate amounted to approximately 71 percent, the top guarantee commitments entered into by the Company are executed with approximately SEK 10.0 million. The Board of Directors has also, based on the authorization granted by the annual general meeting on 7 May 2025, resolved on a directed issue of 1,182,876 ordinary shares to guarantors who have chosen to receive guarantee compensation in the form of newly issued ordinary shares (the "Compensation Issue"). The subscription price in the Directed Issue and the Compensation Issue amounts to SEK 3.68 per ordinary share, corresponding to the exercise price for TO 12. Payment is made in cash and by set-off of the guarantors' claims. Søren Bregenholt, CEO of Alligator Bioscience, comments:"The outcome of the TO 12 warrant exercise, including the directed issue to guarantors, ensures that we have secured the anticipated capital injection in a challenging market environment. We view the strong participation and the fulfilment of the top guarantee commitments as a clear signal of continuedconfidence in our strategy and the long-term potential of mitazalimab. These proceeds allow us to strengthen our financial position and continue advancing toward a pivotal Phase 3 trial together with a future partner." The Directed Issue In accordance with what was communicated by the Company on 9 May 2025, top and bottom guarantee commitments have been entered into to secure the subscription of TO 12 in the event that the exercise rate for TO 12 was below approximately 85 percent. As the exercise rate amounted to approximately 71 percent, the top guarantee commitments entered into by the Company are executed with approximately SEK 10.0 million, corresponding to approximately 14 percent of the total number of TO 12, resulting in TO 12 being exercised to approximately 85 percent, corresponding to a total of approximately SEK 61.5 million. The outcome means that no bottom guarantees are executed. The top guarantee commitments are executed by the Board of Directors resolving on a directed issue of ordinary shares. The Board of Directors has therefore today, based on the authorization granted by the annual general meeting on 7 May 2025, resolved on a directed issue of 2,730,708 ordinary shares to the guarantors to execute the top guarantee commitments. Subscription in the Directed Issue is made at the same subscription price as for TO 12, i.e. SEK 3.68 per ordinary share, and the Company thus receives approximately SEK 10.0 million from the Directed Issue, before issue costs and set-off of an outstanding loan of approximately SEK 6.7 million. The investors who have entered into top guarantee commitments and thereby participate in the Directed Share Issue are presented in the table below. Guarantor/subscriber Number of subscribed ordinary shares Total subscription amount (SEK) Fenja Capital II A/S 1,810,425 6,662,364.00 Birger Jarl 2 AB 125,209 460,769.12 Consentia Group AB 125,209 460,769.12 Johan Carlström 125,209 460,769.12 Ghanem Chouha 75,125 276,460.00 Tony Chouha 75,125 276,460.00 Ulti AB 75,125 276,460.00 Bohr Invest AB 75,125 276,460.00 Niclas Löwgren 62,604 230,382.72 Stefan Hansson 62,604 230,382.72 Great Ventures & Consulting GCV AB 62,604 230,382.72 Axel Lindberg 56,344 207,345.92 Total 2,730,708 10,049,005.44 The Board of Directors has carefully considered the possibility of raising capital through a rights issue and makes the assessment that it is currently for several reasons more advantageous for the Company and its shareholders to raise capital by securing the exercise of TO 12 and to carry out the Directed Issue. The Company wished to ensure in advance that it receives a certain amount from TO 12 and therefore entered into top guarantee commitments with the investors participating in the Directed Issue. The size of the Directed Issue is dependent on the warrant holders' exercise of TO 12. Warrant holders were free to exercise TO 12 and thereby limit the size of the Directed Issue. The Company also believes that a rights issue under the current volatile market conditions would entail higher costs related to any underwriting. Finally, the Company wishes to expand and strengthen its base of professional shareholders to, among other things, improve the liquidity of the Company's share. In light of this, the Board of Directors' overall assessment is that the reasons for securing the exercise of TO 12 and to carry out the Directed Issue with deviation from the shareholders' preferential rights clearly and with sufficient strength outweigh the reasons that justify the main rule that new issues shall be carried out with preferential rights for the shareholders. The subscription price in the Directed Issue has been determined based on negotiations among the guarantors and the Company, in consultation with a financial adviser and through an analysis of several market factors. Therefore, the Board of Directors of the Company considers that the subscription price has been determined on market terms and correctly reflects current market conditions and demand. Thereto, the subscription price in the Directed Issue corresponds to the exercise price for TO 12. Payment in the Directed Issue is made in cash and, with regards to the top guarantor Fenja Capital II A/S, by set-off of the guarantor's claim regarding an outstanding loan. All shares in the Directed Issue have been subscribed and allotted to the top guarantors. Through the Directed Issue, the number of shares in the Company increases by 2,730,708 shares, from a total of 30,890,314 shares to 33,621,022 shares, of which all outstanding shares are ordinary shares. The share capital increases by SEK 2,184,566.40, from SEK 24,712,251.20 to SEK 26,896,817.60. For existing shareholders, the dilution from the Directed Issue amounts to approximately 8 percent based on the number of ordinary shares in the Company after the exercise of TO 12 and the Directed Issue. The total number of votes in the Company after the exercise of TO 12 and the Directed Issue amounts to 33,621,022. The Compensation IssueIn accordance with the agreements on top and bottom guarantees, cash compensation corresponding to 10 percent of the guaranteed amount shall be paid, corresponding to approximately SEK 4.5 million, or 12 percent of the guaranteed amount shall be paid in the form of newly issued ordinary shares in the Company, at a subscription price of SEK 3.68 per ordinary share. In total, eight guarantors have chosen to receive guarantee compensation in the form of newly issued ordinary shares in accordance with the below. Guarantor/subscriber Number of subscribed ordinary shares Total subscription amount (SEK) Fredrik Lundgren 561,684 2,066,997.12 Wilhelm Risberg 561,684 2,066,997.12 Birger Jarl 2 AB 16,304 59,998.72 Ghanem Chouha 9,782 35,997.76 Tony Chouha 9,782 35,997.76 Stefan Hansson 8,152 29,999.36 Great Ventures & Consulting GCV AB 8,152 29,999.36 Axel Lindberg 7,336 26,996.48 Total 1,182,876 4,352,983.68 Due to this, the Board of Directors of Alligator Bioscience has today, based on the authorization granted by the annual general meeting on 7 May 2025, resolved on the Compensation Issue, which comprises a total of 1,182,876 ordinary shares, corresponding to approximately SEK 4.4 million. Payment in the Compensation Issue is made by set-off of each guarantor's claim on guarantee compensation. The guarantors who have not chosen to receive guarantee compensation in the form of ordinary shares will instead receive a cash amount for each guarantee commitment. The cash component of the guarantee compensation amounts to approximately SEK 0.9 million. The subscription price in the Compensation Issue amounts to SEK 3.68 per ordinary share, corresponding to the exercise price of TO 12. The basis for calculating the subscription price was determined through negotiations among the guarantors and the Company, in consultation with a financial adviser and through analysis of a number of market factors. In light of this, it is the Board of Directors' assessment that the subscription price is on market terms. The reasons for the deviation from the shareholders' preferential right are as follows. In accordance with the executed guarantee agreements, guarantee compensation shall be paid either in cash at an amount corresponding to 10 percent of the guaranteed amount or 12 percent of the guaranteed amount in the form of newly issued ordinary shares in the Company, in accordance with the terms and conditions stated above. As a result of the guarantee commitments, each subscriber thus has a claim on the Company regarding guarantee compensation. Each subscriber in the table above has declared its willingness to allow the Company to offset the debt regarding guarantee compensation by carrying out an offset issue. The Compensation Issue is thus carried out in order to fulfil the Company's obligations to the guarantors as a result of the guarantee agreements entered into. The Company's alternative to carrying out the Compensation Issue is to instead settle the guarantee compensation through cash payment. The Board of Directors is of the opinion that - taking into account current market conditions - it is in the interest of the Company's financial position and in the interest of the shareholders to carry out the Compensation Issue on the stated terms and conditions, as the Company will then release funds that strengthen the Company's working capital. Through the Compensation Issue, the number of shares in the Company increases additionally by 1,182,876 shares, from a total of 33,621,022 shares to 34,803,898 shares, of which all outstanding shares are ordinary shares. The share capital increases additionally by SEK 946,300.80, from SEK 26,896,817.60 to SEK 27,843,118.40. For existing shareholders, the dilution from the Compensation Issue amounts to approximately 3.4 percent based on the number of ordinary shares in the Company after the exercise of TO 12, the Directed Issue and the Compensation Issue. The total number of votes in the Company after the exercise of TO 12, the Directed Issue and the Compensation Issue amounts to 34,803,898. Advisers Vator Securities AB acts as Sole Global Coordinator and bookrunner in connection with the rights issue in which TO 12 were issued (the "Rights Issue") and Van Lanschot Kempen N.V. acts as financial adviser to Alligator Bioscience in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 6:00 p.m. CEST on 26 May 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit IMPORTANT INFORMATION The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Alligator Bioscience. The invitation to the persons concerned to subscribe for units consisting of ordinary shares, warrants series TO 12 and warrants series TO 13 in Alligator Bioscience has only been made through the prospectus published by Alligator Bioscience on 24 January 2025. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, Since Alligator Bioscience is considered to conduct protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of ordinary shares may require review by the Inspectorate of Strategic Products (ISP). More information about this can be found on the Company's website, Attachments Alligator Bioscience AB carries out directed issues to guarantors in connection with exercise of warrants series TO 12 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire
Yahoo
26-05-2025
- Business
- Yahoo
Alligator Bioscience Announces European Orphan Drug Designation for HLX22 in Gastric Cancer
LUND, SE / / May 26, 2025 / Alligator Bioscience (STO:ATORX) - Lund, Sweden - 26 May 2025 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Commission has granted orphan drug designation (ODD) to HLX22, an anti-HER2 monoclonal antibody, for the treatment of gastric cancer. HLX22 is being developed by Shanghai Henlius Biotech, Inc. under a sublicense from AbClon, Inc., which had previously licensed the antibody from Alligator. This designation follows the ODD granted by the U.S. Food and Drug Administration (FDA) in March 2025, further highlighting HLX22's potential as a treatment for HER2-positive gastric cancer. Henlius is conducting a global Phase 3 clinical trial (NCT06532006) to evaluate HLX22 in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive metastatic gastric and gastroesophageal junction (GEJ) cancer. Søren Bregenholt, CEO of Alligator Bioscience, commented:"The orphan designation to HLX22 in Europe represents another important regulatory milestone for this program. Following the earlier FDA designation, this reinforces the potential clinical and commercial value of the antibody. While Alligator is not directly involved in the development, we look forward to following its progress as it may contribute future revenue to Alligator." Under the terms of the license agreement, Alligator is entitled to 35% of AbClon's revenue from its sublicense agreement with Henlius. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 3:00 p.m. CEST on 26 May 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit About the European Orphan Drug Designation The European Orphan Drug Designation is granted to medicines intended for the treatment, prevention or diagnosis of life-threatening or chronically debilitating conditions affecting no more than five in 10,000 people in the EU. The designation provides a range of incentives, including protocol assistance, fee reductions, and ten years of market exclusivity following regulatory approval. Attachments Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
20-05-2025
- Business
- Yahoo
Alligator Bioscience Announces Paediatric Study Waiver for Mitazalimab Granted by the European Medicines Agency
LUND, SE / / May 20, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical stage biotechnology company pioneering immuno-oncology therapeutics, today announced that the European Medicines Agency (EMA) has granted a waiver from conducting paediatric clinical trials for Alligator's lead asset mitazalimab. The waiver, issued as part of the Paediatric Investigation Plan (PIP) regulatory process, exempts Alligator from the obligation to conduct pediatric studies with mitazalimab in the treatment of pancreatic cancer. This regulatory milestone removes a key requirement ahead of potential future marketing authorization submissions in the European Union. Mitazalimab, a CD40 agonist antibody, is currently being evaluated in the OPTIMIZE-1 Phase 2 clinical trial in combination with chemotherapy for patients with previously untreated metastatic pancreatic cancer. Recent 24-month follow-up data demonstrate a survival rate of 29.4% for patients treated with mitazalimab in combination with mFOLFIRINOX, which is more than triple the estimated 8% survival rate for FOLFIRINOX alone. The median overall survival was reported at 14.9 months, and the median duration of response was 12.6 months, both indicating a favorable safety profile and encouraging survival outcomes. "This decision by the EMA allows us to continue advancing mitazalimab through late-stage development with a clear regulatory path to approval," said Søren Bregenholt, CEO of Alligator Bioscience. "While we remain committed to the highest standards of patient safety, this waiver recognizes that pancreatic cancer is extremely rare in pediatric populations and supports our focused efforts to address the significant unmet medical need in adults." Alligator will continue to engage with regulatory authorities in Europe and the United States as it prepares for potential registrational steps for mitazalimab. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 2:30 p.m. CEST on 20 May 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit Attachments Alligator Bioscience announces paediatric study waiver for mitazalimab granted by the European Medicines Agency SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
20-05-2025
- Business
- Yahoo
Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 12
LUND, SE / / May 20, 2025 / Alligator Bioscience (STO:ATORX) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The exercise period for warrants series TO 12 ("TO 12") in Alligator Bioscience AB ("Alligator Bioscience" or the "Company") ended on 19 May 2025. The preliminary outcome indicates that a total of 13,984,837,000 TO 12 were exercised for subscription of 13,984,837 new ordinary shares for approximately SEK 51.5 million, corresponding to an exercise rate of approximately 71 percent. The preliminary outcome thus indicates that the top guarantee commitments that the Company has entered into will be executed with approximately SEK 10.0 million, corresponding to approximately 14 percent of the total number of TO 12, resulting in TO 12 being exercised up to approximately 85 percent, corresponding to a total of approximately SEK 61.5 million. The final outcome and additional information on the execution of the top guarantee commitments will be published in a separate press release. The exercise period for TO 12 took place during the period 5 - 19 May 2025. One thousand (1,000) TO 12 entitled the holder to subscribe for one (1) new ordinary share in the Company at a subscription price of SEK 3.68 per share. The preliminary outcome indicates that 13,984,837,000 TO 12, corresponding to approximately 71 percent of all TO 12, were exercised for subscription of a total of 13,984,837 ordinary shares. The preliminary outcome thus indicates that the top guarantee commitments that the Company has entered into will be executed with approximately SEK 10.0 million, corresponding to approximately 14 percent of the total number of TO 12, resulting in TO 12 being exercised up to approximately 85 percent, corresponding to a total of approximately SEK 61.5 million. The final outcome and additional information on the execution of the top guarantee commitments will be published in a separate press release which is expected to be announced on 21 May 2025. AdvisersVator Securities AB acts as Sole Global Coordinator and bookrunner in connection with the rights issue in which TO 12 were issued (the " Rights Issue ") and Van Lanschot Kempen N.V. acts as financial adviser to Alligator Bioscience in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 12:30 p.m. CEST on 20 May 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit . IMPORTANT INFORMATION The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Alligator Bioscience. The invitation to the persons concerned to subscribe for units consisting of ordinary shares, warrants series TO 12 and warrants series TO 13 in Alligator Bioscience has only been made through the prospectus published by Alligator Bioscience on 24 January 2025. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, . Since Alligator Bioscience is considered to conduct protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act ( Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of ordinary shares may require review by the Inspectorate of Strategic Products (ISP). More information about this can be found on the Company's website, . Attachments Alligator Bioscience AB announces preliminary outcome of exercise of warrants series TO 12 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
